NIO Valuation
Is N3IA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of N3IA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate N3IA's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate N3IA's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for N3IA?
Key metric: As N3IA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is N3IA's PS Ratio? | |
|---|---|
| PS Ratio | 1.2x |
| Sales | CN¥63.13b |
| Market Cap | CN¥73.73b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.2x |
| Enterprise Value/EBITDA | -4x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does N3IA's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.7x | ||
7270 Subaru | 0.4x | 2.0% | JP¥1.8t |
2238 Guangzhou Automobile Group | 0.3x | 9.2% | HK$77.7b |
7201 Nissan Motor | 0.1x | 2.6% | JP¥1.5t |
XPEV XPeng | 2.2x | 30.7% | US$11.3b |
N3IA NIO | 1.2x | 23.1% | €10.2b |
Price-To-Sales vs Peers: N3IA is expensive based on its Price-To-Sales Ratio (1.2x) compared to the peer average (0.7x).
Price to Sales Ratio vs Industry
How does N3IA's PS Ratio compare vs other companies in the European Auto Industry?
| 5 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 5 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: N3IA is expensive based on its Price-To-Sales Ratio (1.2x) compared to the European Auto industry average (0.3x).
Price to Sales Ratio vs Fair Ratio
What is N3IA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.2x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate N3IA's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €4.60 | €6.26 +36.0% | 29.1% | €12.00 | €3.84 | n/a | 26 |
| Nov ’25 | n/a | €6.26 0% | 28.0% | €11.75 | €3.69 | n/a | 26 |
| Oct ’25 | n/a | €6.04 0% | 29.4% | €11.59 | €3.64 | n/a | 26 |
| Sep ’25 | n/a | €6.05 0% | 29.2% | €11.51 | €3.68 | n/a | 25 |
| Aug ’25 | n/a | €6.29 0% | 29.4% | €11.58 | €3.71 | n/a | 25 |
| Jul ’25 | n/a | €6.60 0% | 29.1% | €11.63 | €3.72 | n/a | 27 |
| Jun ’25 | n/a | €6.79 0% | 31.2% | €13.15 | €3.68 | n/a | 27 |
| May ’25 | n/a | €6.90 0% | 31.2% | €13.34 | €3.73 | n/a | 27 |
| Apr ’25 | n/a | €7.08 0% | 28.1% | €13.23 | €4.42 | n/a | 26 |
| Mar ’25 | €5.01 | €9.48 +89.2% | 29.1% | €16.44 | €4.63 | n/a | 27 |
| Feb ’25 | €5.21 | €9.78 +87.8% | 26.1% | €16.55 | €6.93 | n/a | 27 |
| Jan ’25 | €8.48 | €10.14 +19.6% | 28.0% | €17.34 | €6.79 | n/a | 25 |
| Dec ’24 | €6.78 | €12.24 +80.6% | 29.9% | €20.57 | €7.07 | n/a | 25 |
| Nov ’24 | n/a | €12.73 0% | 29.4% | €20.62 | €7.09 | n/a | 25 |
| Oct ’24 | €8.34 | €12.95 +55.3% | 27.5% | €20.47 | €7.03 | n/a | 25 |
| Sep ’24 | n/a | €13.03 0% | 27.3% | €20.23 | €6.98 | n/a | 26 |
| Aug ’24 | €13.47 | €10.98 -18.5% | 31.7% | €19.12 | €6.06 | n/a | 27 |
| Jul ’24 | n/a | €10.07 0% | 27.2% | €18.03 | €6.04 | n/a | 27 |
| Jun ’24 | €6.62 | €12.73 +92.5% | 25.0% | €22.48 | €8.68 | n/a | 25 |
| May ’24 | €6.98 | €13.14 +88.2% | 27.3% | €22.65 | €8.74 | n/a | 25 |
| Apr ’24 | €8.38 | €13.99 +67.0% | 30.1% | €24.10 | €8.89 | n/a | 27 |
| Mar ’24 | €8.82 | €16.01 +81.6% | 27.5% | €25.23 | €9.38 | €5.01 | 27 |
| Feb ’24 | n/a | €16.83 0% | 25.6% | €26.31 | €9.78 | €5.21 | 28 |
| Jan ’24 | €9.52 | €17.27 +81.5% | 25.5% | €26.39 | €9.80 | €8.48 | 28 |
| Dec ’23 | n/a | €17.73 0% | 28.7% | €32.30 | €10.95 | €6.78 | 27 |
| Nov ’23 | n/a | €28.52 0% | 33.7% | €64.92 | €14.23 | n/a | 25 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.